Le Lézard
Classified in: Health

Artemis Research Named 2018 Clinical Site Team of the Year by PharmaTimes


SAN DIEGO, May 17, 2018 /PRNewswire-iReach/ -- Artemis Institute for Clinical Research, a leader in Principal Investigator and Patient Focused clinical research has been named 2018 Clinical Site of the Year for The Americas by PharmaTimes. Designed to recognize and reward the talent and passion of industry and academic researchers in the US, North, South and Central America, this annual competition drew over 240 teams competing for a coveted spot in the finals.

The Clinical Site Team distinction is awarded to the team who successfully completes a three-stage entry process designed to benchmark skills against peers. The independent judging panel of high-level industry leaders compiled by PharmaTimes measured participants based on innovation in clinical trial operations, mitigation of safety risk, and excellence in patient recruitment rewarding teamwork and creative problem-solving. "Site Team of the Year is an important distinction," stated panel judge Suzanne Day. "This is a well-deserved and well-earned first place award for a team that represents the future of clinical research."

"Every Artemis team member is empowered to embrace innovative ways of working to ensure we provide the best customer experience every day to both our patients and sponsors," commented Dr. Vishaal Mehra, CEO of Artemis Institute for Clinical Research. "We are proud to receive this award and congratulate the team for their hard work."

A complete list of winners in all categories can be found here.

About Artemis Institute for Clinical Research
Artemis Research is a leading Principal Investigator and Patient Focused clinical research company dedicated to advancing medical treatments through rigorous, process-driven trial management. Artemis specializes in Psychiatry/Neurology, Internal Medicine, and Women's Health Initiatives. Established in 2008 by colleagues who bring more than 50 years of combined research experience, the Artemis team is committed to a more thoughtful and professional approach to conducting clinical trials. With multiple locations serving Southern California including San Diego, San Marcos and a soon to open Riverside branch, each Artemis site is fully equipped to conduct complex clinical research trials on behalf of sponsors and study patients. To learn more or join a study please visit: https://artemis-research.com/

Media Contact: Jacqueline Keller, Artemis Institute for Clinical Research, 858-278-3647 ext. 303, [email protected]

News distributed by PR Newswire iReach: https://ireach.prnewswire.com

SOURCE Artemis Institute for Clinical Research


These press releases may also interest you

at 13:26
In a bid to foster excellence and innovation in the healthcare industry, the esteemed Dr. Vidal Sheen proudly announces the launch of The Dr. Vidal Sheen Grant for Healthcare Students. With a robust focus on academic prowess, compassionate care, and...

at 13:17
Rexall is proud to unveil its first Pharmacist Care Walk-In Clinic in Barrie, Ontario on Friday, April 19. Located at 353 Duckworth Street, the clinic will offer personalized care to the community while providing immediate pharmacist treatment for...

at 13:13
Caring for communities extends beyond life-changing work in operating rooms and physician offices. Hartford HealthCare leadership today highlighted its corporate responsibility to environmental, social and economic sustainability in announcing its...

at 13:04
Concept Medical, a pioneer in innovative drug delivery technologies, proudly announces the commencement of its groundbreaking IDE clinical study, "MAGICAL-ISR" using MagicTouch ? Sirolimus drug coated balloon (DCB), for the management of in-stent...

at 12:30
The American College of Physicians (ACP) today released an update of its 2017 guideline with clinical recommendations for the use of newer pharmacological treatments of adults with Type 2 diabetes. The clinical guideline is based on the best...

at 12:10
Pieris Pharmaceuticals, Inc. today announced that its Board of Directors has approved a 1-for-80 reverse stock split of the Company's common stock, par value $0.001, which will be effective at 5:00 pm Eastern Time on April 22, 2024. The Company's...



News published on and distributed by: